EDAP to Present at H.C. Wainwright Annual Conference, CEO to Lead Fireside Chat and Meetings

EDAP TMS SA, a leading robotic energy-based therapy company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ryan Rhodes will lead a fireside chat and one-on-one investor meetings, with live and archived webcasts available on the company's investor relations website. EDAP continues to develop its proprietary Focal One therapy for prostate cancer and other indications.

EDAP TMS SA, a leading company in robotic energy-based therapies, has announced that its CEO, Ryan Rhodes, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is scheduled to take place from September 8-10, 2025, in New York City. Rhodes is set to lead a fireside chat and conduct one-on-one investor meetings during the event. The live and archived webcasts of the presentation will be available on the company's investor relations website [1].

EDAP TMS SA specializes in developing, manufacturing, and distributing minimally invasive medical devices using ultrasound technology. The company's flagship product, the Focal One® system, is a leading prostate focal therapy controlled by urologists. The Focal One® system has the potential to expand to multiple indications beyond prostate cancer [1].

The participation of Ryan Rhodes in the conference offers an opportunity for investors and industry peers to gain insights into the company's developments and future plans. The fireside chat and one-on-one investor meetings provide a platform for direct engagement with the company's leadership. Additionally, the availability of webcasts allows for broader reach and accessibility, potentially engaging a wider audience [1].

Institutional investors have shown interest in EDAP TMS SA, with recent hedge fund activity indicating both additions and removals from portfolios. For example, BANQUE TRANSATLANTIQUE SA removed 720,499 shares from their portfolio in Q2 2025, while UBS GROUP AG added 139,990 shares to their portfolio during the same period [2]. Analysts have also issued positive ratings on the stock, with Piper Sandler and HC Wainwright & Co. issuing "Overweight" and "Buy" ratings, respectively [2].

Despite the positive outlook, it is important to note that the absence of detailed financial updates or performance metrics in the announcement could imply potential struggles the company may be facing. Additionally, the focus on a single product, the Focal One®, might indicate limited diversification in their product offerings, which can be a risk if market dynamics change [1].

In summary, EDAP TMS SA's participation in the H.C. Wainwright 27th Annual Global Investment Conference presents an opportunity for investors to engage with the company's leadership and gain insights into its developments. The fireside chat and one-on-one investor meetings, along with the availability of webcasts, provide a platform for direct engagement and broader reach. However, investors should also consider the potential risks and uncertainties associated with the company's focus on a single product and the absence of detailed financial updates.

References:
[1] https://www.quiverquant.com/news/EDAP+TMS+SA+CEO+Ryan+Rhodes+to+Speak+at+H.C.+Wainwright+27th+Annual+Global+Investment+Conference
[2] https://www.biospace.com/press-releases/health-canada-grants-marketing-authorization-for-an-additional-indication-of-bayers-nubeqa-darolutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer-mcspc